Alnylam Pharmaceuticals Inc (HAM:DUL) Stock Price, Trades & News

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	2.61
Equity-to-Asset	0.24
Debt-to-Equity	0.94
Debt-to-EBITDA	1.08
Interest Coverage	3.08
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.12	Distress Grey Safe
Beneish M-Score	-1.87	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	47.9
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	72.36
	Future 3-5Y Total Revenue Growth Rate Estimate	30.42

Momentum Rank

4/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	63.72
	9-Day RSI	49.91
	14-Day RSI	44.57
	3-1 Month Momentum %	-5.04
	6-1 Month Momentum %	-15.77
	12-1 Month Momentum %	-39.15

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.05
	Quick Ratio	2.99
	Cash Ratio	2.19
	Days Inventory	30.69
	Days Sales Outstanding	62.39
	Days Payable	42.6

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-2.2
	Shareholder Yield %	0.05

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	79.65
	Operating Margin %	20.81
	Net Margin %	16.82
	EBITDA Margin %	24.55
	FCF Margin %	17.04
	OCF Margin %	18.96
	ROE %	109.09
	ROA %	16.11
	ROIC %	79.83
	3-Year ROIIC %	380.7
	ROC (Joel Greenblatt) %	158.92
	ROCE %	31.44
	Years of Profitability over Past 10-Year	1
	Moat Score	6
	Tariff Resilience Score	8

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	43.91
	Forward PE Ratio	34.42
	PE Ratio without NRI	29.6
	Price-to-Owner-Earnings	150.55
	PS Ratio	6.76
	PB Ratio	23.33
	Price-to-Tangible-Book	23.31
	Price-to-Free-Cash-Flow	39.63
	Price-to-Operating-Cash-Flow	35.63
	EV-to-EBIT	26.29
	EV-to-Forward-EBIT	18.58
	EV-to-EBITDA	25.07
	EV-to-Forward-EBITDA	20.01
	EV-to-Revenue	6.15
	EV-to-Forward-Revenue	5.31
	EV-to-FCF	36.06
	Price-to-GF-Value	0.45
	Price-to-Median-PS-Value	0.21
	Price-to-Graham-Number	5.54
	Price-to-Net-Current-Asset-Value	75.88
	Earnings Yield (Greenblatt) %	3.8
	FCF Yield %	2.59

Financials (Next Earnings Date:2026-10-30 Est.)

Annual Quarterly TTM

HAM:DUL's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Alnylam Pharmaceuticals Inc Executives

Details

GF Value™: €453.42

HAM:DUL

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Medium warning signs with DUL. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	4,131.185
	EPS (TTM) (€)	4.624
	Beta	0.1845
	3-Year Sharpe Ratio	0.18
	3-Year Sortino Ratio	0.35
	Volatility %	37.71
	14-Day RSI	44.57
	14-Day ATR (€)	7.094676
	20-Day SMA (€)	201.14
	12-1 Month Momentum %	-39.15
	52-Week Range (€)	177.05 - 419
	Shares Outstanding (Mil)	133.81

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Alnylam Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Alnylam Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Fourth quarter earnings conference call for 2026	2027-02-12 08:30	In 175 days
Annual report for 2026	2027-02-12	In 174 days
Fourth quarter earnings results for 2026	2027-02-12	In 174 days
Third quarter earnings conference call for 2026	2026-10-30 08:30	In 70 days
Third quarter earnings results for 2026	2026-10-30	In 69 days
Second quarter earnings conference call for 2026	2026-07-30 08:30	253.50 (+0.36%)
Second quarter earnings results for 2026	2026-07-30	253.50 (+0.36%)
RNAi Roundtable: ALN-6400, Targeting Plasminogen to Address Rare Bleeding Disorders	2026-06-25 11:00	265.20 (+5.49%)
Goldman Sachs Annual Healthcare Conference	2026-06-09 11:20	251.80 (-4.44%)
General meeting for 2026	2026-05-20 10:30	248.20 (+2.06%)

Show

Entries

Alnylam Pharmaceuticals Inc Frequently Asked Questions

What is Alnylam Pharmaceuticals Inc(HAM:DUL)'s stock price today?

The current price of HAM:DUL is €202.60. The 52 week high of HAM:DUL is €419.00 and 52 week low is €177.05.

When is next earnings date of Alnylam Pharmaceuticals Inc(HAM:DUL)?

The next earnings date of Alnylam Pharmaceuticals Inc(HAM:DUL) is 2026-10-30 Est..

Does Alnylam Pharmaceuticals Inc(HAM:DUL) pay dividends? If so, how much?

Alnylam Pharmaceuticals Inc(HAM:DUL) does not pay dividend.

Press Release

	Subject	Date
	ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations	2026-08-19
	Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm	2026-08-16
	NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm	2026-08-14
	ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law	2026-08-05
	ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law	2026-08-03
	Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm	2026-07-30
	Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation	2026-07-30
	Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced -- Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz	2026-07-30
	Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress	2026-07-30
	Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results	2026-07-16

10/Page

Articles on Alnylam Pharmaceuticals Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.